Literature DB >> 27998499

Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients.

Arun Kumar Yadav1, Ashok Kumar Mehrotra2, S P Agnihotri3, Shivani Swami4.   

Abstract

BACKGROUND: CAT IV regimen or the standardized drug regimen (SDR) under the Revised National Control Program (RNTCP) uses six second-line anti-tubercular drugs in the initial intensive phase (IP). These drugs have many side effects and toxicity; they are less efficacious and have poor acceptability. The present study was conducted to evaluate the efficacy and outcome of Cat-IV regimen and the factors which influence the treatment outcome in MDR TB patients.
METHODS: It was a prospective observational study, which was done in the CAT II treatment failure, LPA proven MDR TB patients, above the age of 18 years, who were referred to DOTS Plus center for treatment. The study was approved by the hospital ethics committee and patient consent was obtained before inclusion.
RESULTS: We observed culture conversion in 63.04% and ADR in 96.5%, default in 15.65%, and death in11.3% cases. The factors which influenced outcome included low body weight, long duration of illness cavitatory disease and indulgence in both tobacco & alcohol. The radiological favorable response strongly and significantly correlated with the bacteriological and clinical response during the IP.
CONCLUSION: We suggest that the efficacy can be further augmented by reducing default and controlling deaths which accounts for substantial numbers and occur mostly during IP.
Copyright © 2016 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CAT IV regimen; MDR TB; RNTCP

Mesh:

Substances:

Year:  2016        PMID: 27998499     DOI: 10.1016/j.ijtb.2016.09.013

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  3 in total

1.  Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.

Authors:  D M Kokebu; S Ahmed; R Moodliar; C-Y Chiang; G Torrea; A Van Deun; R L Goodall; I D Rusen; S K Meredith; A J Nunn
Journal:  Int J Tuberc Lung Dis       Date:  2022-08-01       Impact factor: 3.427

2.  Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience.

Authors:  Abhijeet Singh; Rajendra Prasad; Ram Awadh Singh Kushwaha; Rahul Srivastava; Belur Hosmane Giridhar; Viswesvaran Balasubramanian; Amita Jain
Journal:  Lung India       Date:  2019 Sep-Oct

3.  Treatment Outcomes Associated with Multidrug-resistant Tuberculosis.

Authors:  Nitin Gupta; Pankaj Jorwal
Journal:  J Glob Infect Dis       Date:  2018 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.